News Release

Validations Now Under Way

Date: July 5, 2000

CDNX Trading Symbol: WXI
World Wide Web: http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc., (the "company") is pleased to announce that the company has signed contracts with two laboratories in Canada to test Tetrodin and validate several of the company's key findings generated in China. It is believed that this gives credibility to our Chinese research and deters any potential questioning of those results. These laboratories hold validations from H.P.B., F.D.A. and E.M.E.A. or Germany.

The basics to be re-tested are product purity, certificate of analysis and the validation method. Further, to verify that in-vitro metabolism findings are consistent with those found to date.

As these verifications are not trial and error but validations of the results of prior trials conducted in China, the company believes the time frame for completion will be measured in only a few months.

Further contracts with other labs are under negotiation.

Tetrodin has been developed by the company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. The company has also begun tests on the usage of Tetrodin as a potent analgesic.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.